Qureight analyses of Insilico Medicine’s Phase IIa rentosertib data support preliminary efficacy results and future trial expansion
Qureight’s synthetic study arms validate clinical efficacy in pioneering rare lung disease treatment
The Potential for Deep Learning Technology in Clinical Trials
Journal of Clinical Studies
Deep Learning Quantitative Computed Tomography Analysis in the Australian Idiopathic Pulmonary Fibrosis Registry
ATS Journals
Deep Learning-based Disease Severity Biomarkers on CT; Posthoc Analysis in a Phase 2a Placebo-controlled Study of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis
ATS Journals
Monte Carlo External Control Arm Generation Utilising Real-world Patient Data and Deep Learning-based Quantitative CT Metrics Demonstrates Treatment Effect in the Atlas IPF Trial
ATS Journals
Deep Learning-Based Short-Term Disease Progression Evaluation Supersedes Automated Baseline CT Phenotype in Predicting Outcomes in Idiopathic Pulmonary Fibrosis
ATS Journals
Deep Learning-Based Quantitative CT and CT Phenotype Classification Independently Predict Mortality in Idiopathic Pulmonary Fibrosis, a Prospective Observational Cohort Study
ATS Journals
Deep Learning-based Quantitative CT and Proteomics for Predicting Outcomes in Idiopathic Pulmonary Fibrosis
ATS Journals
Dose-Dependent Change of Inhaled Pirfenidone Seen in Lung Volume and Fibrosis Quantification in Patients With IPF: A Deep Learning Image-Based Analysis of Data From the ATLAS Phase 1b Trial
ATS Journals
Qureight partners With Cumberland Pharmaceuticals to advance innovative Idiopathic Pulmonary Fibrosis treatment research
Rein Therapeutics and Qureight broaden life science collaboration
Business Weekly
Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF
Qureight showcases the power of AI-driven image analytics across eight presentations at the 2025 ATS International Conference
How is deep learning imaging advancing drug discovery for fibrosis?
Drug Discovery World
Appointment of Dr. Paul Ford MD, PhD as Senior Clinical Development Advisor
Qureight Board of Directors elects Dr. Neil Johnston to the Board as Non-Executive Chair
The role of NHS Big Data and AI technology in unlocking the future of lung and heart disease treatment
pharmaphorum